Enable Recite me Accessibility Tools:
Accessibility Options
To find out more, please see here.

GBS3

Principle Investigator:
Lilian Ugwumadu

This trial is looking at whether testing pregnant women to see if they carry group B Streptococcus (GBS) reduces the risk of infection in newborn babies compared to the current strategy in place in the UK. The current strategy in the UK is to offer antibiotics during labour to women who are considered at risk of their baby developing GBS infection (Risk Factor Based Strategy).

There are two different tests, which GBS3 are comparing against the current strategy:

  • A test at an antenatal appointment approximately 3-5 weeks before expected pregnancy due date (Enriched Culture Medium Testing)
  • Bedside test at start of labour (Intrapartum Rapid Testing)

All hospitals taking part have been randomly allocated to either undertake testing pregnant women for GBS carriage or continue following current UK GBS strategy. This means all women who are pregnant and give birth at this hospital will be tested for GBS and treated in the same manner (unless advised otherwise by your doctor or midwife).

ASPH has been allocated to undertake testing pregnant women for GBS carriage. The test allocated is a test at an antenatal appointment approximately 3-5 weeks before expected pregnancy due date.

CRAFT

Principle Investigator:
Lilian Ugwumadu

In the UK we offer extra screening to pregnant women who have risk factors for having a premature baby (under 37 weeks). 1 in every 13 babies born in the UK will be born premature and late miscarriages (14-23+6 weeks) are rare. CRAFT is trying to understand the role that a previous emergency caesarean has on this risk, by collecting information from a large group of women who have previously had a caesarean section in labour. This will help us to understand how previous caesarean sections can affect later pregnancies and what we can do to reduce the risks.

LOCI

Principle Investigator:
Lilian Ugwumadu

In order for you to conceive naturally, an egg will need to be released from your ovary. For women with PCOS, this does not always happen, and therefore we need to give medicines to help your body release an egg. There are two drugs we can give to help you release an egg; one called ‘clomifene’ and another called ‘letrozole’. There is another drug called ‘metformin’ that we can also give you at the same time as these other drugs, but we are not sure if this carries any additional benefit. Overall, we are not sure which drugs are best for ovulation induction and a successful pregnancy outcome. The purpose of this study is to test which drugs are best.

Women in the study will take part in up to 6 treatment cycles where letrozole or clomifene is taken with or without metformin. These drugs are already widely used and considered safe, but the results of LOCI will provide important insights on which combination of drugs works best.

UBaP

Principle Investigator:
Karin Leslie

This research aims to investigate how women’s blood pressure responds after birth and assess the time it takes to return to normal ranges, in women who had a hypertensive disorder in pregnancy. This will highlight how many women continue to experience high blood pressure after they have given birth and how often a woman’s General Practitioner (GP) will need to monitor their blood pressure in the immediate few weeks after birth. This research will identify gaps in the care of women in the postnatal period and use the information to help maternity care services provide better care so that women can lead healthier lives and reduce their risk of heart disease.

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.